Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

Study Summary

This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. retifanlimab will be administered as monotherapy or in combination with other immunotherapy or targeted agents.

Conditions

Endometrial Cancer

Interventions / Drugs

retifanlimab epacadostat pemigatinib INCAGN02385 INCAGN02390

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment206 participants

Primary Completion—

Lead SponsorIncyte Corporation

Data Retrieved2026-04-11 02:55:29.647449+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.